Our team

The board

Stephanie Monaghan O'Brien
Ken Kelley
Michael Watson
Mike Watson

In Memory of Mike Watson

We are so very sad to announce that Mike Watson unexpectedly passed away on Saturday 27 August 2022.

Mike was a fundamental part of the formation and success of our companies. He was Executive Chairman at VaxEquity, and co-founder and CEO of MEVOX. Over his long and distinguished career, working in the UK, France, and the USA, he made a significant impact on global vaccine R&D, clinical development, vaccine introduction and vaccination policy for diseases including HPV, polio, and influenza. He also thought beyond vaccines, exploring how novel technologies and platforms such as mRNA could be used therapeutically. His thinking and work had a significant impact on global public health. We are privileged to have worked alongside such an empathic, enthusiastic, and exceptional person. We will continue Mike’s inspiring work to improve human health all around the world.

Ken Kelley

Chair of Board

Kenneth J. Kelley.  Mr. Kelley serves as Chairman of our Board and advises on strategic direction, corporate partnering, financing and product development.  He brings over 35 years of entrepreneurial, venture capital, operational and technical biotechnology experience to our team. 

Mr. Kelley is very active in the infectious disease biotechnology sector, serving on several Boards of Directors and mentoring their CEOs.  His directorships include IDBiologics, Meissa Vaccines, Public Health Vaccines, and SeromYx Systems.  From 2016 to 2018, Mr. Kelley served as a White House Presidential Executive Fellow and a Senior Advisor to the U.S. National Institutes of Health and the National Institute of Allergy and Infectious Diseases, Vaccine Research Center and to the Assistant Secretary of Preparedness and Response.   During this same period, Mr. Kelley served as a Trustee of the Sabin Vaccine Institute and chaired its R&D Committee. 

From 2015 to 2016, Mr. Kelley served as an Advanced Leadership Fellow at Harvard University working on global preparedness for epidemics and pandemics.  From 2007 to 2015, Mr. Kelley was co-founder, CEO and Chairman of PaxVax, Inc., a specialty vaccine company acquired by Emergent BioSolutions, Inc., where his team developed an oral cholera vaccine, Vaxchora.  Previously,

Mr. Kelley was a venture capitalist at K2 BioVentures, Latterell Venture Partners and Institutional Venture Partners. Mr. Kelley earned an M.B.A. from Stanford University and a B.A. in Biochemical Sciences from Harvard University and is a Fellow in the American Institute for Medical and Biological Engineering (AIMBE).

Stephanie Monaghan O'Brien, JD


Stephanie O’Brien represents Morningside Ventures and has extensive experience in working with venture-backed companies focused on novel science.

She focuses on early-stage companies, working with CEOs on building the management team and developing business plans. She has served on numerous private and public company boards, including Apellis Pharmaceuticals (APLS), Aduro Biotech (ADRO), ViOptix, Meissa Vaccines, Vigeo Therapeutics, and College Vine, Inc.

She received her AB degree, cum laude, from Harvard College and her JD degree from New York University School of Law. Prior to attending law school, Stephanie worked for Chase Manhattan Bank, NA, where she completed the loan officer credit training program and then worked in international portfolio analysis.

After law school, Stephanie spent nine years as a corporate lawyer with Hale and Dorr in the Boston and Washington, DC offices, working primarily with venture capital finance and startup companies.

Mike Watson


Over 20 years of global vaccines experience from discovery through to policy launch and implementation in the UK, Europe, and USA with Sanofi Pasteur, Merck (MSD), Acambis and most recently building and leading Moderna’s infectious diseases and vaccines, venture. 

As well as taking 8 vaccines to first in man, 3 to phase 2/3, and 3 to licensure, recommendation and launch, he has extensive experience with novel platforms & technologies, global vaccines (Gardasil/HPV, Polio, and Influenza) and national and global vaccination innovation (Pediacel, Dengvaxia, Polio and Influenza). 

He is driven by the exceptional opportunity that vaccines give him to combine cutting-edge science, working with extraordinary people and impacting lives everywhere.

Mike also sits on the board of Meissa Vaccines and the diagnostics Foundation FIND.

Michael Watson